These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8142739)

  • 1. [Biotest position on HIV-1 seroconversions in 1990 in 11 patients, treated with beta-propiolactone/uv virus inactivated PPSB].
    Pustoslemsek P; Kloft M; Kotitschke R
    Infusionsther Transfusionsmed; 1993 Dec; 20(6):344-6. PubMed ID: 8142739
    [No Abstract]   [Full Text] [Related]  

  • 2. Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences.
    Heinrich D; Sugg U; Brackmann HH; Stephan W; Lissner R
    Dev Biol Stand; 1987; 67():311-7. PubMed ID: 3649316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute HIV-1 infection in patients with hemophilia B treated with beta-propiolactone-UV-inactivated clotting factor.
    Kleim JP; Bailly E; Schneweis KE; Brackmann HH; Hammerstein U; Hanfland P; van Loo B; Oldenburg J
    Thromb Haemost; 1990 Oct; 64(2):336-7. PubMed ID: 2125380
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term tolerance and recovery of beta-propiolactone/ultraviolet (beta PL/UV) treated PPSB in chimpanzees.
    Stephan W; Kotitschke R; Prince AM; Brotman B
    Thromb Haemost; 1981 Aug; 46(2):511-4. PubMed ID: 7302890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monitoring of sterilization procedures for plasma derivatives using bacteriophages].
    Dichtelmüller H; Stephan W
    Immun Infekt; 1988 Feb; 16(1):18-20. PubMed ID: 3283031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of the hepatitis safety of a beta-propiolactone/ultraviolet treated factor IX concentrate (PPSB).
    Heinrich D; Kotitschke R; Berthold H
    Thromb Res; 1982 Oct; 28(1):75-83. PubMed ID: 7157232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of hepatitis viruses and HIV in plasma and plasma derivatives by treatment with beta-propiolactone/UV irradiation.
    Stephan W
    Curr Stud Hematol Blood Transfus; 1989; (56):122-7. PubMed ID: 2642784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Virus safety of labile plasma products from the German viewpoint].
    Stephan W
    Beitr Infusionsther; 1989; 24():40-5. PubMed ID: 2481547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HIV seroconversion in hemophilia A patient after transfusion of anti-HIV negative blood components.
    Ungkanont A; Atichartakarn V; Chiewsilp P
    J Med Assoc Thai; 1992 Feb; 75(2):120-2. PubMed ID: 1645050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of thrombogenicity of beta-propiolactone/ultraviolet (beta-PL/UV) treated PPSB in chimpanzees.
    Kotitschke R; Stephan W; Prince AM; Brotman B
    Thromb Res; 1983 May; 30(3):235-44. PubMed ID: 6868023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insufficient inactivation of HIV-1 in human cryo poor plasma by beta-propiolactone: results from a highly accurate virus detection method.
    Norley SG; Löwer J; Kurth R
    Biologicals; 1993 Sep; 21(3):251-8. PubMed ID: 8117438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV transfusion suit killed because blood was the patient's.
    AIDS Policy Law; 1999 Jan; 14(1):15. PubMed ID: 11366184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Discrepancies in the statistics of HIV-positive persons should be corrected].
    Högman CF; Messeter L
    Lakartidningen; 1993 May; 90(19):1839. PubMed ID: 8502010
    [No Abstract]   [Full Text] [Related]  

  • 14. [The risk of substitution therapy with blood and blood products].
    Baumgarten R
    Z Arztl Fortbild (Jena); 1994 Jan; 88(1):3-4. PubMed ID: 8154136
    [No Abstract]   [Full Text] [Related]  

  • 15. PROPIOLACTONE PLUS ULTRAVIOLET-TREATED PLASMA WITHOUT HEPATITIS. SIX YEARS' EXPERIENCE.
    LOGRIPPO GA; WOLFRAM BR; BRUSH BE
    Arch Surg; 1964 Apr; 88():721-4. PubMed ID: 14107028
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined use of ultraviolet irradiation and beta propiolactone sterilization of sera infected with a virus.
    SMOLENS J; STOKES J
    Proc Soc Exp Biol Med; 1954 Jul; 86(3):538-9. PubMed ID: 13194713
    [No Abstract]   [Full Text] [Related]  

  • 17. [Nosocomial HIV transmission at a Danish hospital department].
    Katzenstein TL; Nielsen C; Gerstoft J
    Ugeskr Laeger; 1999 Nov; 161(46):6364-5. PubMed ID: 10611838
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of combined treatment of serum containing hepatitis B virus with beta-propiolactone and ultraviolet irradiation.
    Stephan W; Berthold H; Prince AM
    Vox Sang; 1981 Sep; 41(3):134-8. PubMed ID: 7331286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen-reduction systems for blood components: the current position and future trends.
    Seghatchian J; de Sousa G
    Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond HIV, HBV and HCV--how to deal with other viruses?
    Minor PD
    Dev Biol (Basel); 2002; 108():15-9. PubMed ID: 12220138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.